{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:53:59Z","timestamp":1791881639252,"version":"4.3.4"},"reference-count":236,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia","doi-asserted-by":"publisher","award":["2026MS0108"],"award-info":[{"award-number":["2026MS0108"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Metabolic reprogramming is increasingly recognised as a central determinant of bladder cancer heterogeneity, immune regulation and treatment response. This review integrates genetic, epigenetic, microenvironmental and therapeutic evidence to explain how bladder cancer redistributes carbon and nitrogen across glycolysis, lipid synthesis and oxidation, amino-acid metabolism and mitochondrial respiration. Alterations in FGFR3, PIK3CA, MYC, TP53\/RB1 and KDM6A establish distinct, context-dependent metabolic dependencies, while hypoxia, extracellular-matrix mechanics and treatment selection reinforce metabolic plasticity. These programmes influence not only energy production and biosynthesis but also ferroptosis, genome stability and chromatin or RNA regulation. Lactate, adenosine, kynurenine and asparagine further connect tumour metabolism to regulatory T cells, myeloid cells, innate immune sensing and CD8-positive T cell function, thereby shaping resistance to chemotherapy and immune-checkpoint blockade. Therapeutic opportunities include targeting glycolysis, fatty-acid and cholesterol metabolism, glutamine and proline metabolism, arginine auxotrophy and metabolite-mediated immune suppression. However, pathway redundancy, cellular heterogeneity and shared metabolic requirements between tumour and immune cells constrain unselected treatment. Urine, tissue, blood and imaging metabolomics offer complementary routes to diagnosis, prognostication and real-time response monitoring, but require harmonised sampling, functional flux measurements and prospective validation. A clinically useful strategy will therefore depend on defining metabolic vulnerabilities by genotype, cell type, spatial context and treatment stage, and on pairing pharmacodynamic biomarkers with rational combinations and local delivery where appropriate.<\/jats:p>","DOI":"10.3390\/cancers18193202","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:02:27Z","timestamp":1791194547000},"page":"3202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Reprogramming in Bladder Cancer: Molecular Drivers, Immune Regulation and Therapeutic Opportunities"],"prefix":"10.3390","volume":"18","author":[{"given":"Shaolin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Chifeng University, Chifeng 024005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Chifeng University, Chifeng 024005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Chifeng University, Chifeng 024005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Pu","sequence":"additional","affiliation":[{"name":"General Office, Affiliated Hospital of Chifeng University, Chifeng 024005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Chifeng University, Chifeng 024005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2101-7162","authenticated-orcid":false,"given":"Changgang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Chifeng University, Chifeng 024005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"ref_1","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma In Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1038\/s41598-022-09438-9","article-title":"Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time","volume":"12","author":"Xu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2023.05.037","article-title":"Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors","volume":"85","author":"Groeneveld","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1111\/cas.15047","article-title":"The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets","volume":"112","author":"Burns","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1038\/s41467-023-41139-3","article-title":"Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ","volume":"14","author":"Yao","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1158\/0008-5472.CAN-12-1329","article-title":"FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth","volume":"72","author":"Du","year":"2012","journal-title":"Cancer Res."},{"key":"ref_16","first-page":"2196","article-title":"Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: Insights from gemcitabine- and cisplatin-resistant models","volume":"18","author":"Kawahara","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1038\/onc.2015.511","article-title":"Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells","volume":"35","author":"King","year":"2016","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/(SICI)1097-0215(19990420)84:2<169::AID-IJC13>3.0.CO;2-F","article-title":"Over-expression and amplification of the c-myc gene in human urothelial carcinoma","volume":"84","author":"Christoph","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.7150\/thno.102730","article-title":"DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization","volume":"15","author":"Deng","year":"2025","journal-title":"Theranostics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41419-026-08714-0","article-title":"Nuclear hexokinase 2 couples hyperglycemia to MYC-driven glycolytic and stemness programs in bladder cancer","volume":"17","author":"Liu","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Afonso, J., Barbosa-Matos, C., Silvestre, R., Pereira-Vieira, J., Gon\u00e7alves, S.M., Mendes-Alves, C., Parpot, P., Pinto, J., Carapito, \u00c2., and Guedes de Pinho, P. (2024). Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect. Cancers, 16.","DOI":"10.3390\/cancers16071418"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Afonso, J., Gon\u00e7alves, C., Costa, M., Ferreira, D., Santos, L., Longatto-Filho, A., and Baltazar, F. (2023). Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy. Cancers, 15.","DOI":"10.3390\/cancers15030982"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pan, M., Tao, T., Kong, D., and Gong, H. (2026). Aerobic glycolysis in bladder cancer: Research advances and targeted therapy potential. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1799955"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41419-024-06446-7","article-title":"USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_25","first-page":"63","article-title":"CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis","volume":"44","author":"Shen","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"\u00d6zden-Y\u0131lmaz, G., Savas, B., Bursal\u0131, A., Eray, A., Ar\u0131ba\u015f, A., Senturk, S., Karaca, E., Karak\u00fclah, G., and Erkek-Ozhan, S. (2023). Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines. Cells, 12.","DOI":"10.3390\/cells12060836"},{"key":"ref_27","first-page":"1","article-title":"The cancer driver genes IDH1\/2, JARID1C\/KDM5C, and UTX\/KDM6A: Crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism","volume":"51","author":"Chang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Loras, A., Segovia, C., and Ruiz-Cerd\u00e1, J.L. (2021). Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer. Cancers, 13.","DOI":"10.3390\/cancers13112719"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: Molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Martinez, V.G., Munera-Maravilla, E., Bernardini, A., Rubio, C., Suarez-Cabrera, C., Segovia, C., Lodewijk, I., Due\u00f1as, M., Mart\u00ednez-Fern\u00e1ndez, M., and Paramio, J.M. (2019). Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.01125"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41467-025-68132-2","article-title":"Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer","volume":"17","author":"Singh","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-021-01369-9","article-title":"KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1","volume":"20","author":"Liu","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s42003-024-07067-8","article-title":"Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin \u03b21 localization","volume":"7","author":"Wang","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41388-022-02487-4","article-title":"Src: Coordinating metabolism in cancer","volume":"41","author":"Pelaz","year":"2022","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-024-04867-8","article-title":"Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0960-9822(99)80091-8","article-title":"The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell","volume":"9","author":"Hart","year":"1999","journal-title":"Curr. Biol. CB"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nature04185","article-title":"A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation","volume":"438","author":"Zeng","year":"2005","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/ERC-12-0328","article-title":"Androgen activates \u03b2-catenin signaling in bladder cancer cells","volume":"20","author":"Li","year":"2013","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"56842","DOI":"10.18632\/oncotarget.10863","article-title":"Targeting XBP1-mediated \u03b2-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/hmg\/ddaf024","article-title":"LRP8 inhibits bladder cancer cell ferroptosis by activating the Wnt\/\u03b2-catenin-SCD1 positive feedback loop","volume":"34","author":"Zhao","year":"2025","journal-title":"Hum. Mol. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"Dupont","year":"2011","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncb2756","article-title":"Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts","volume":"15","author":"Calvo","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41419-025-08222-7","article-title":"Matrix stiffness maintains bladder cancer stemness via integrin-nuclear skeleton axis","volume":"16","author":"Tao","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41389-022-00420-8","article-title":"Lipids in cancer: A global view of the contribution of lipid pathways to metastatic formation and treatment resistance","volume":"11","author":"Vasseur","year":"2022","journal-title":"Oncogenesis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101529","DOI":"10.1016\/j.molmet.2022.101529","article-title":"New dawn for cancer cell death: Emerging role of lipid metabolism","volume":"63","author":"Zhang","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1126863","article-title":"P53 regulates mitochondrial respiration","volume":"312","author":"Matoba","year":"2006","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","article-title":"TIGAR, a p53-inducible regulator of glycolysis and apoptosis","volume":"126","author":"Bensaad","year":"2006","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9620","DOI":"10.7150\/thno.44176","article-title":"LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1","volume":"10","author":"Logotheti","year":"2020","journal-title":"Theranostics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e014408","DOI":"10.1136\/jitc-2025-014408","article-title":"Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma","volume":"14","author":"Ding","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"Yecies","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kami Reddy, K.R., Putluri, V., Piyarathna, D.W.B., Park, J.H., Arun, A.K., Jorvekar, S.B., Dou, Y., Hassan, M.K., Amara, C.S., and Kamal, A.H.M. (2026). Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression. Cell Commun. Signal.","DOI":"10.1186\/s12964-026-03058-w"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1002\/mco2.421","article-title":"Potential therapies targeting nuclear metabolic regulation in cancer","volume":"4","author":"Chen","year":"2023","journal-title":"MedComm"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/onc.2017.13","article-title":"Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1\u03b1","volume":"36","author":"Wan","year":"2017","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cac2.12158","article-title":"The role of the HIF-1\u03b1\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.7150\/ijbs.126325","article-title":"NOP2-mediated 5-methylcytosine Regulates Lipid Metabolism Reprogramming to Prime Tumors for Ferroptosis in Bladder Cancer Progression","volume":"22","author":"Cheng","year":"2026","journal-title":"Int. J. Biol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wang, Z., Zhou, Z., Yang, S., Zhao, Z., Li, X., Liu, X., Cheng, G., Xu, R., Li, Q., and Xing, D. (2026). Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1777092"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2546219","DOI":"10.1080\/15384047.2025.2546219","article-title":"Hypoxia-induced PYCR1 regulates glycolysis and histone lactylation to promote bladder cancer progression and metastasis via SLC6A14\/Glutamine metabolism","volume":"26","author":"Li","year":"2025","journal-title":"Cancer Biol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.6367","article-title":"Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment","volume":"265","author":"Dinh","year":"2025","journal-title":"J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/cam4.1109","article-title":"Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer","volume":"6","author":"Sahu","year":"2017","journal-title":"Cancer Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhu, B., Cai, Y., Zhu, S., Zhao, H., Ying, X., Jiang, C., and Zeng, J. (2022). Alteration in glycolytic\/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration. BMC Cancer, 22.","DOI":"10.1186\/s12885-021-09064-0"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1038\/s41467-021-26421-6","article-title":"Pparg signaling controls bladder cancer subtype and immune exclusion","volume":"12","author":"Tate","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3762\/bjnano.5.52","article-title":"The softening of human bladder cancer cells happens at an early stage of the malignancy process","volume":"5","author":"Ramos","year":"2014","journal-title":"Beilstein J. Nanotechnol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/nyas.14358","article-title":"Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection","volume":"1473","author":"Ghasemi","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e71059","DOI":"10.1002\/cam4.71059","article-title":"Piezo1\/ITGB1 Synergizes With Ca(2+)\/YAP Signaling to Propel Bladder Carcinoma Progression via a Stiffness-Dependent Positive Feedback Loop","volume":"14","author":"Ma","year":"2025","journal-title":"Cancer Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41419-025-07935-z","article-title":"The ETS transcription factor GABPA inhibits bladder cancer aggressiveness by repressing extracellular matrix deposition and mechanotransduction signaling","volume":"16","author":"Dai","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"30775","DOI":"10.1021\/acsami.5c25973","article-title":"Matrix Mechanics Governs Mechano-Metabolic Adaptation across Cancer Grades in Bladder Spheroids","volume":"18","author":"Metwally","year":"2026","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Dong, X., Chen, Z., Chen, Y., Xiao, Z., Zhang, J., Li, Y., and Du, H. (2026). Mechanical stress, metabolic reprogramming and stromal remodeling: An emerging paradigm in the bladder cancer mechano-micro-environment. Front. Genet., 17.","DOI":"10.3389\/fgene.2026.1896399"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1021\/acsbiomaterials.5c00136","article-title":"Structural and Mechanical Characterization of Collagen-Hyaluronan Hydrogels Used to Study Cancer Cell Invasion through the Bladder Wall","volume":"11","author":"Metwally","year":"2025","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2018.03.055","article-title":"Metabolomics and Isotope Tracing","volume":"173","author":"Jang","year":"2018","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/0008-5472.CAN-21-0403","article-title":"PKM2 Is Essential for Bladder Cancer Growth and Maintenance","volume":"82","author":"Xia","year":"2022","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-18-0063","article-title":"The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance","volume":"17","author":"Woolbright","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Woolbright, B.L., Rajendran, G., Abbott, E., Martin, A., Didde, R., Dennis, K., Harris, R.A., and Taylor, J.A. (2023). Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine Model of Bladder Cancer. Cancers, 15.","DOI":"10.3390\/cancers15061654"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11219","DOI":"10.1074\/jbc.M113.535989","article-title":"Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1\u03b1","volume":"289","author":"Zhao","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/mc.23894","article-title":"CircST6GALNAC6 Inhibits Glycolysis of Bladder Cancer by Regulating PRKN\/HK1 Signaling Pathway","volume":"64","author":"Zuo","year":"2025","journal-title":"Mol. Carcinog."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41419-026-08691-4","article-title":"PSMD11 stabilizes PGM3 by antagonizing Parkin to promote bladder cancer progression through energy metabolism reprogramming","volume":"17","author":"Cheng","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","article-title":"CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression","volume":"19","author":"Kirk","year":"2000","journal-title":"EMBO J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"245.e9","DOI":"10.1016\/j.urology.2014.03.031","article-title":"Prognostic significance of lactate\/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder","volume":"84","author":"Choi","year":"2014","journal-title":"Urology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e14614","DOI":"10.1002\/advs.202514614","article-title":"Early Detection of Chemotherapy-Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium ((2)H) Metabolic Imaging: In Vitro and in Vivo Assessments","volume":"13","author":"Kong","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1002\/jcp.27129","article-title":"Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT\/mTOR\/SREBP-1c axis","volume":"234","author":"Tao","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zeng, F., Lan, Y., Wang, N., Huang, X., Zhou, Q., and Wang, Y. (2022). Ferroptosis: A new therapeutic target for bladder cancer. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1043283"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/0008-5472.CAN-21-0646","article-title":"Oxidized Low-Density Lipoprotein Links Hypercholesterolemia and Bladder Cancer Aggressiveness by Promoting Cancer Stemness","volume":"81","author":"Yang","year":"2021","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1089\/dna.2011.1315","article-title":"The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: Implications for tumor progression","volume":"30","author":"Fredericks","year":"2011","journal-title":"DNA Cell Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"101282","DOI":"10.1016\/j.neo.2026.101282","article-title":"White-to-brown adipose switching promotes bladder cancer progression","volume":"73","author":"Gao","year":"2026","journal-title":"Neoplasia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1038\/s41388-025-03474-1","article-title":"ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via 53BP1 acetylation","volume":"44","author":"Luo","year":"2025","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1038\/s41388-024-03139-5","article-title":"m(6)A modification of lipoyltransferase 1 inhibits bladder cancer progression by activating cuproptosis","volume":"43","author":"Du","year":"2024","journal-title":"Oncogene"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature10642","article-title":"Reductive carboxylation supports growth in tumour cells with defective mitochondria","volume":"481","author":"Mullen","year":"2011","journal-title":"Nature"},{"key":"ref_89","first-page":"2189","article-title":"Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis","volume":"44","author":"Sun","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101340","DOI":"10.1016\/j.tranon.2022.101340","article-title":"Long noncoding RNA UCA1 promotes glutamine-driven anaplerosis of bladder cancer by interacting with hnRNP I\/L to upregulate GPT2 expression","volume":"17","author":"Zhao","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101120","DOI":"10.1016\/j.neo.2024.101120","article-title":"RUNX2 enhances bladder cancer progression by promoting glutamine metabolism","volume":"60","author":"Huang","year":"2025","journal-title":"Neoplasia"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Muhammad, N., Lee, H.M., and Kim, J. (2020). Oncology Therapeutics Targeting the Metabolism of Amino Acids. Cells, 9.","DOI":"10.20944\/preprints202007.0698.v1"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/0008-5472.CAN-13-1702","article-title":"Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging","volume":"74","author":"Allen","year":"2014","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10863-021-09887-3","article-title":"PYCR1 promotes bladder cancer by affecting the Akt\/Wnt\/\u03b2-catenin signaling","volume":"53","author":"Du","year":"2021","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.18632\/aging.204333","article-title":"SENP3 affects the expression of PYCR1 to promote bladder cancer proliferation and EMT transformation by deSUMOylation of STAT3","volume":"14","author":"Li","year":"2022","journal-title":"Aging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s42255-022-00582-0","article-title":"Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix","volume":"4","author":"Kay","year":"2022","journal-title":"Nat. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e186648","DOI":"10.1172\/JCI186648","article-title":"Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling","volume":"135","author":"Wei","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bju.15205","article-title":"Tryptophan-kynurenine ratio as a biomarker of bladder cancer","volume":"127","author":"Lee","year":"2021","journal-title":"BJU Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1178646919868978","DOI":"10.1177\/1178646919868978","article-title":"The Plasma [Kynurenine]\/[Tryptophan] Ratio and Indoleamine 2,3-Dioxygenase: Time for Appraisal","volume":"12","author":"Badawy","year":"2019","journal-title":"Int. J. Tryptophan Res. IJTR"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1038\/s41467-023-41218-5","article-title":"AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e2408599","DOI":"10.1002\/advs.202408599","article-title":"Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer","volume":"12","author":"Deng","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.freeradbiomed.2023.09.017","article-title":"CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway","volume":"208","author":"Gao","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s12967-025-06547-7","article-title":"SRSF1-mediated alternative splicing regulates bladder cancer progression and cisplatin sensitivity through HIF1A\/BNIP3\/mitophagy axis","volume":"23","author":"Wu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e172336","DOI":"10.1172\/jci.insight.172336","article-title":"Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer","volume":"9","author":"Piyarathna","year":"2024","journal-title":"JCI Insight"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41419-024-07068-9","article-title":"Mesenchymal stem cells in tumor microenvironment: Drivers of bladder cancer progression through mitochondrial dynamics and energy production","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e27427","DOI":"10.1016\/j.heliyon.2024.e27427","article-title":"The down-regulation of GADD45B leads to a conversion of cellular oxidative phosphorylation to glycolysis and promotes the progression of bladder cancer","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Alhozeel, B., Pandey, S.K., Shteinfer-Kuzmine, A., Santhanam, M., and Shoshan-Barmatz, V. (2024). Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer. Cells, 13.","DOI":"10.3390\/cells13070627"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1038\/s41388-026-03903-9","article-title":"YME1L1 degradation by TRIM21 inhibits bladder cancer proliferation, metastasis, and mitochondrial function","volume":"45","author":"Sun","year":"2026","journal-title":"Oncogene"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"104551","DOI":"10.1016\/j.isci.2022.104551","article-title":"The origin of bladder cancer from mucosal field effects","volume":"25","author":"Bondaruk","year":"2022","journal-title":"iScience"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.celrep.2019.01.095","article-title":"Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis","volume":"26","author":"Majewski","year":"2019","journal-title":"Cell Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/OTT.S358008","article-title":"CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming","volume":"15","author":"Li","year":"2022","journal-title":"OncoTargets Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"41610","DOI":"10.1038\/s41598-025-25534-y","article-title":"Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance","volume":"15","author":"Yu","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Brice\u00f1o, P., Rivas-Ya\u00f1ez, E., Rosemblatt, M.V., Parra-Tello, B., Far\u00edas, P., Vargas, L., Simon, V., C\u00e1rdenas, C., Lladser, A., and Salazar-Onfray, F. (2021). CD73 Ectonucleotidase Restrains CD8+ T Cell Metabolic Fitness and Anti-tumoral Activity. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.638037"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.labinv.2022.100040","article-title":"Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer","volume":"103","author":"Izawa","year":"2023","journal-title":"Lab. Investig. A J. Tech. Methods Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00262-026-04400-4","article-title":"CD39\/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer","volume":"75","author":"Furriel","year":"2026","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"113643","DOI":"10.1016\/j.celrep.2023.113643","article-title":"Intercellular crosstalk shapes purinergic metabolism and signaling in cancer cells","volume":"43","author":"Hesse","year":"2024","journal-title":"Cell Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"11786469211065612","DOI":"10.1177\/11786469211065612","article-title":"Indoleamine 2,3-Dioxygenase-1 Expression is Changed During Bladder Cancer Cell Invasion","volume":"15","author":"Santos","year":"2022","journal-title":"Int. J. Tryptophan Res. IJTR"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41419-026-08798-8","article-title":"TRIM28-mediated SUMOylation of SREBF1 drives PD-L1 N-glycosylation and immune evasion in bladder cancer","volume":"17","author":"Chen","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Scholtes, M.P., de Jong, F.C., Zuiverloon, T.C.M., and Theodorescu, D. (2021). Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13020288"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e148549","DOI":"10.1172\/JCI148549","article-title":"Fighting in a wasteland: Deleterious metabolites and antitumor immunity","volume":"132","author":"Watson","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semcancer.2022.02.010","article-title":"Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer","volume":"86","author":"Wang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41423-020-00556-w","article-title":"Implications of metabolism-driven myeloid dysfunctions in cancer therapy","volume":"18","author":"Strauss","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mco2.6","article-title":"Metabolism in tumor microenvironment: Implications for cancer immunotherapy","volume":"1","author":"Shi","year":"2020","journal-title":"MedComm"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"G\u00fcnther, J., D\u00e4britz, J., and Wirthgen, E. (2019). Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01801"},{"key":"ref_125","first-page":"41","article-title":"HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1\/PKM2 pathway","volume":"42","author":"Lv","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Xiong, Q., Feng, D., Wang, Z., Ying, Y., Xu, C., Wei, Q., Zeng, S., and Yang, L. (2022). Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.836939"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"112485","DOI":"10.1016\/j.intimp.2024.112485","article-title":"CircZNF609 inhibited bladder cancer immunotherapy sensitivity via enhancing fatty acid uptake through IGF2BP2\/CD36 pathway","volume":"137","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-22-2213","article-title":"Cancer-Associated Fibroblast-Derived miR-146a-5p Generates a Niche That Promotes Bladder Cancer Stemness and Chemoresistance","volume":"83","author":"Zhuang","year":"2023","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: From biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Baek, S.W., Yoon, S.Y., Kim, S.K., and Leem, S.H. (2026). Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27125152"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Jin, M., Cai, Z., Bu, M., Liu, J., and Zhang, X. (2026). From molecular networks to translational intervention: Current progress in the mechanisms of gemcitabine resistance in bladder cancer. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1860957"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s42003-024-07284-1","article-title":"SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway","volume":"8","author":"Gong","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e110620","DOI":"10.15252\/embj.2022110620","article-title":"IDH2 stabilizes HIF-1\u03b1-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer","volume":"42","author":"Shigeta","year":"2023","journal-title":"EMBO J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbalip.2018.06.005","article-title":"Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer","volume":"1864","author":"Wen","year":"2019","journal-title":"Biochim. Biophys. Acta. Mol. Cell Biol. Lipids"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7150\/jca.83856","article-title":"Acyl-coenzyme A: Cholesterol acyltransferase inhibitor avasimibe suppresses tumorigenesis and induces G1-phase cell-cycle arrest by activating PPAR\u03b3 signaling pathway in bladder cancer","volume":"15","author":"Peng","year":"2024","journal-title":"J. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1158\/0008-5472.CAN-23-3703","article-title":"M6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis","volume":"84","author":"Zeng","year":"2024","journal-title":"Cancer Res."},{"key":"ref_138","first-page":"101059","article-title":"Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"218282","DOI":"10.1016\/j.canlet.2026.218282","article-title":"Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer","volume":"642","author":"Yu","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e13404","DOI":"10.1111\/cpr.13404","article-title":"YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer","volume":"56","author":"Su","year":"2023","journal-title":"Cell Prolif."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"eabi8602","DOI":"10.1126\/sciadv.abi8602","article-title":"Lactate supports a metabolic-epigenetic link in macrophage polarization","volume":"7","author":"Noe","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"216964","DOI":"10.1016\/j.canlet.2024.216964","article-title":"Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation","volume":"593","author":"Yu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"117553","DOI":"10.1016\/j.bcp.2025.117553","article-title":"LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1","volume":"243","author":"Tang","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12943-023-01856-1","article-title":"CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer","volume":"22","author":"Xie","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol Induces CD8(+) T Cell Exhaustion in the Tumor Microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab."},{"key":"ref_150","first-page":"3671","article-title":"Oncogenic roles of the cholesterol metabolite 25-hydroxycholesterol in bladder cancer","volume":"19","author":"Wang","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_151","first-page":"316","article-title":"Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1","volume":"42","author":"Zhang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e2305922","DOI":"10.1002\/advs.202305922","article-title":"G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via PI3K\/Akt Activation in Bladder Cancer","volume":"11","author":"Zheng","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s42003-025-08174-w","article-title":"Nanoparticle-mediated targeting of PGC-1\u03b1 reveals critical metabolic pathways in bladder cancer metastasis","volume":"8","author":"Liu","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","article-title":"Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer","volume":"40","author":"Ma","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e04688","DOI":"10.1002\/advs.202504688","article-title":"Gut Parabacteroides distasonis-derived Indole-3-Acetic Acid Promotes Phospholipid Remodeling and Enhances Ferroptosis Sensitivity via the AhR-FASN Axis in Bladder Cancer","volume":"12","author":"Li","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/2159-8290.CD-20-0844","article-title":"Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy","volume":"10","author":"Fendt","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: Looking forward","volume":"21","author":"Chandel","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1158\/0008-5472.CAN-25-0024","article-title":"Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer","volume":"86","author":"Wu","year":"2026","journal-title":"Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Chelakkot, C., Chelakkot, V.S., Shin, Y., and Song, K. (2023). Modulating Glycolysis to Improve Cancer Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032606"},{"key":"ref_163","first-page":"155426","article-title":"Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1","volume":"126","author":"Liu","year":"2024","journal-title":"Phytomed. Int. J. Phyther. Phytopharm."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Wu, M., Lin, P., Xu, L., Yu, Z., Chen, Q., Gu, H., and Liu, C. (2020). Prognostic Role of Serum Lactate Dehydrogenase in Patients With Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00677"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Wei, X., Chai, Y., Li, Z., Che, X., Zhang, Y., Zhou, Z., and Wang, X. (2023). Up-regulated serum lactate dehydrogenase could become a poor prognostic marker in patients with bladder cancer by an evidence-based analysis of 2,182 patients. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1233620"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Daneshmandi, S., Wegiel, B., and Seth, P. (2019). Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11040450"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Qiao, T., Xiong, Y., Feng, Y., Guo, W., Zhou, Y., Zhao, J., Jiang, T., Shi, C., and Han, Y. (2021). Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.632364"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2174\/1871520621666210726142814","article-title":"Anticancer Effects of Cinnamaldehyde Through Inhibition of ErbB2\/HSF1\/LDHA Pathway in 5637 Cell Line of Bladder Cancer","volume":"22","author":"Aminzadeh","year":"2022","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"108479","DOI":"10.1016\/j.abb.2020.108479","article-title":"Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism","volume":"690","author":"Sellam","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ncb2629","article-title":"ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect","volume":"14","author":"Yang","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s42003-025-08130-8","article-title":"Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and activate antitumor immune responses","volume":"8","author":"Jin","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1620\/tjem.2025.J049","article-title":"Oxymatrine Inhibits PKM2-Mediated Glycolysis and Enhances Cisplatin Sensitivity in Bladder Cancer","volume":"269","author":"Zhang","year":"2026","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12943-015-0399-9","article-title":"3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants","volume":"14","author":"Konstantakou","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12944-025-02431-x","article-title":"SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase","volume":"24","author":"Wang","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/2326-6066.CIR-21-0802","article-title":"In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1\/PD-L1 Therapies","volume":"10","author":"Denis","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"35783","DOI":"10.1038\/srep35783","article-title":"Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPAR\u03b3 signalling pathway","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-021-00493-8","article-title":"Metformin targets Clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c\/FASN axis","volume":"6","author":"Deng","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1111\/cas.14615","article-title":"Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus","volume":"111","author":"Saito","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","article-title":"Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma","volume":"6","author":"Afzal","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Wang, J.X., Choi, S.Y.C., Niu, X., Kang, N., Xue, H., Killam, J., and Wang, Y. (2020). Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218363"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.celrep.2019.08.068","article-title":"Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy","volume":"29","author":"Renner","year":"2019","journal-title":"Cell Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cmet.2023.06.003","article-title":"Beggars banquet: Metabolism in the tumor immune microenvironment and cancer therapy","volume":"35","author":"Zou","year":"2023","journal-title":"Cell Metab."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Li, Z., Wang, Q., Huang, X., Yang, M., Zhou, S., Li, Z., Fang, Z., Tang, Y., Chen, Q., and Hou, H. (2023). Lactate in the tumor microenvironment: A rising star for targeted tumor therapy. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1113739"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1016\/j.apsb.2024.07.003","article-title":"Strategies for intravesical drug delivery: From bladder physiological barriers and potential transport mechanisms","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jpba.2006.06.044","article-title":"Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer","volume":"43","author":"Vainchtein","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/0008-5472.CAN-21-3822","article-title":"Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer","volume":"82","author":"Shangguan","year":"2022","journal-title":"Cancer Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e2202993","DOI":"10.1002\/advs.202202993","article-title":"Bladder Cancer-Derived Small Extracellular Vesicles Promote Tumor Angiogenesis by Inducing HBP-Related Metabolic Reprogramming and SerRS O-GlcNAcylation in Endothelial Cells","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res. An. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1013713905833","article-title":"Metabolomics\u2014The link between genotypes and phenotypes","volume":"48","author":"Fiehn","year":"2002","journal-title":"Plant Mol. Biol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Chen, Y., Li, E.M., and Xu, L.Y. (2022). Guide to Metabolomics Analysis: A Bioinformatics Workflow. Metabolites, 12.","DOI":"10.3390\/metabo12040357"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Wishart, D.S., Cheng, L.L., Copi\u00e9, V., Edison, A.S., Eghbalnia, H.R., Hoch, J.C., Gouveia, G.J., Pathmasiri, W., Powers, R., and Schock, T.B. (2022). NMR and Metabolomics-A Roadmap for the Future. Metabolites, 12.","DOI":"10.3390\/metabo12080678"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"9979","DOI":"10.1039\/D2CC03598G","article-title":"Addressing big data challenges in mass spectrometry-based metabolomics","volume":"58","author":"Guo","year":"2022","journal-title":"Chem. Commun."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Wittmann, B.M., Stirdivant, S.M., Mitchell, M.W., Wulff, J.E., McDunn, J.E., Li, Z., Dennis-Barrie, A., Neri, B.P., Milburn, M.V., and Lotan, Y. (2014). Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115870"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"115966","DOI":"10.1016\/j.jpba.2024.115966","article-title":"Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection","volume":"240","author":"Krupa","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"9802","DOI":"10.1038\/s41598-023-36874-y","article-title":"Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry","volume":"13","author":"Nieczaj","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"115473","DOI":"10.1016\/j.jpba.2023.115473","article-title":"Targeted and untargeted urinary metabolic profiling of bladder cancer","volume":"233","author":"Ruman","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCO.0000000000001137","article-title":"Metabolic landscape in bladder cancer","volume":"37","author":"Razavi","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_203","first-page":"211","article-title":"Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI)","volume":"3","author":"Sumner","year":"2007","journal-title":"Metabolomics Off. J. Metabolomic Soc."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1007\/s00216-016-9797-0","article-title":"The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancer","volume":"408","author":"Zhou","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.clnu.2024.05.003","article-title":"A panel of four plasma amino acids is a promising biomarker for newly diagnosed bladder cancer","volume":"43","author":"Liu","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Wang, Z., Liu, X., Liu, X., Sun, H., Guo, Z., Zheng, G., Zhang, Y., and Sun, W. (2019). UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6354-1"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.euf.2017.04.005","article-title":"Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder","volume":"4","author":"Piyarathna","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Dom\u00ednguez, R., Gonz\u00e1lez-Dom\u00ednguez, \u00c1., Sayago, A., and Fern\u00e1ndez-Recamales, \u00c1. (2020). Recommendations and Best Practices for Standardizing the Pre-Analytical Processing of Blood and Urine Samples in Metabolomics. Metabolites, 10.","DOI":"10.3390\/metabo10060229"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12291-024-01187-y","article-title":"Metabolomic Biomarkers for Prognosis in Non-Muscle Invasive Bladder Cancer: A Comprehensive Systematic Review and Meta-Analysis","volume":"40","author":"Singh","year":"2025","journal-title":"Indian J. Clin. Biochem. IJCB"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Jacyna, J., Kordalewska, M., Artymowicz, M., Markuszewski, M., Matuszewski, M., and Markuszewski, M.J. (2022). Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis. Cancers, 14.","DOI":"10.3390\/cancers14051210"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1007\/s00216-023-04826-0","article-title":"Targeted quantitative metabolomics with a linear mixed-effect model for analysis of urinary nucleosides and deoxynucleosides from bladder cancer patients before and after tumor resection","volume":"415","author":"Artymowicz","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Madej, A., Forma, E., Golberg, M., Kami\u0144ski, R., Paneth, P., Kobos, J., R\u00f3\u017ca\u0144ski, W., and Lipi\u0144ski, M. (2022). (13)C Natural Isotope Abundance in Urothelium as a New Marker in the Follow-Up of Patients with Bladder Cancer. Cancers, 14.","DOI":"10.3390\/cancers14102423"},{"key":"ref_213","first-page":"636","article-title":"Two metabolic enzymes, LDH and FASN, serum levels in Bladder cancer patients","volume":"15","author":"Fattahi","year":"2024","journal-title":"Casp. J. Intern. Med."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Xu, Y., Xia, Z., Sun, X., Wei, B., Fu, Y., Shi, D., and Zhu, Y. (2023). Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1111319"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Song, T., He, K., Ning, J., Li, W., Xu, T., Yu, W., Rao, T., and Cheng, F. (2022). Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.930038"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Shen, C., Suo, Y., Guo, J., Su, W., Zhang, Z., Yang, S., Wu, Z., Fan, Z., Zhou, X., and Hu, H. (2024). Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1430583"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"109657","DOI":"10.1016\/j.isci.2024.109657","article-title":"Performance of (18)F-FDG PET\/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer","volume":"27","author":"Li","year":"2024","journal-title":"iScience"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clgc.2023.02.004","article-title":"Added Clinical Value of (18)F-FDG-PET\/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy","volume":"21","author":"Oosterbaan","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Zhang-Yin, J., Girard, A., Marchal, E., Lebret, T., Homo Seban, M., Uhl, M., and Bertaux, M. (2023). PET Imaging in Bladder Cancer: An Update and Future Direction. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040606"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s41747-024-00464-y","article-title":"Advances and prospects in deuterium metabolic imaging (DMI): A systematic review of in vivo studies","volume":"8","author":"Pan","year":"2024","journal-title":"Eur. Radiol. Exp."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLI.0000000000001170","article-title":"Deuterium Metabolic Imaging of the Human Abdomen at Clinical Field Strength","volume":"61","author":"Wodtke","year":"2026","journal-title":"Invest Radiol."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Bizzarri, F.P., Campetella, M., Russo, P., Palermo, G., Moosavi, S.K., Rossi, F., D\u2019Amico, L., Cret\u00ec, A., Gavi, F., and Panio, E. (2025). Prognostic Value of PLR, SIRI, PIV, SII, and NLR in Non-Muscle Invasive Bladder Cancer: Can Inflammatory Factors Influence Pathogenesis and Outcomes?. Cancers, 17.","DOI":"10.3390\/cancers17132189"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0AN00382D","article-title":"Evaluation of a gas sensor array and pattern recognition for the identification of bladder cancer from urine headspace","volume":"136","author":"Weber","year":"2011","journal-title":"Analyst"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"17170","DOI":"10.1021\/acs.analchem.3c02523","article-title":"Global Urinary Volatolomics with (GC\u00d7)GC-TOF-MS","volume":"95","author":"Myridakis","year":"2023","journal-title":"Anal. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"125296","DOI":"10.1016\/j.talanta.2023.125296","article-title":"Exploiting volatile fingerprints for bladder cancer diagnosis: A scoping review of metabolomics and sensor-based approaches","volume":"268","author":"Carapito","year":"2024","journal-title":"Talanta"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41416-022-01785-8","article-title":"Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer","volume":"127","author":"Lett","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Pinto, J., Carapito, \u00c2., Amaro, F., Lima, A.R., Carvalho-Maia, C., Martins, M.C., Jer\u00f3nimo, C., Henrique, R., Bastos, M.L., and Guedes de Pinho, P. (2021). Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics. Metabolites, 11.","DOI":"10.3390\/metabo11040199"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00345-022-04136-7","article-title":"LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer","volume":"40","author":"Oto","year":"2022","journal-title":"World J. Urol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.31557\/APJCP.2019.20.7.2219","article-title":"Urine and Serum Exosomes as Novel Biomarkers in Detection of Bladder Cancer","volume":"20","author":"Elsharkawi","year":"2019","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"217352","DOI":"10.1016\/j.canlet.2024.217352","article-title":"Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer","volume":"609","author":"Steiner","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/s41467-023-38403-x","article-title":"Using mass spectrometry imaging to map fluxes quantitatively in the tumor ecosystem","volume":"14","author":"Stancliffe","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41592-024-02392-6","article-title":"Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling","volume":"21","author":"Nunes","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euros.2023.03.006","article-title":"Single-nucleus and Spatially Resolved Intratumor Subtype Heterogeneity in Bladder Cancer","volume":"51","author":"Lindskrog","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","article-title":"Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response","volume":"86","author":"Merrill","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.urolonc.2024.12.264","article-title":"Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer","volume":"43","author":"Daneshmand","year":"2025","journal-title":"Urol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:29:26Z","timestamp":1791880166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":236,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193202"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193202","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]}}}